2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Titel:
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Auteur:
Leuzy, A. Ashton, N. J. Mattsson-Carlgren, N. Dodich, A. Boccardi, M. Corre, J. Drzezga, A. Nordberg, A. Ossenkoppele, R. Zetterberg, H. Blennow, K. Frisoni, G. B. Garibotto, V. Hansson, O.
Verschenen in:
European journal of nuclear medicine and molecular imaging